Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: Correlation with outcomes

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 707-714

  Grim, Shellee A ^a   Berger, Karen ^a,d   Teng, Christine ^b   Gupta, Sandeep ^c   Layden, Jennifer E ^a   Janda, William M ^a   Clark, Nina M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Podiatry   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Candidaemia; Initiation; Mortality; Survival

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; AGE; ANTIFUNGAL SUSCEPTIBILITY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CORRELATION ANALYSIS; CRITICAL ILLNESS; EARLY INTERVENTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; SURVIVAL; THERAPY DELAY; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDEMIA; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863079846     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr511     Document Type: Article

References (26)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27: 520-32.
2. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
3. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001- 2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52.
4. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999; 1: 247-61.
5. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
6. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
7. Leibovici L, Shraga I, Drucker M et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86.
8. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
9. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
10. Fernandez J, Erstad BL, Petty W et al. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009; 64: 402-7.
11. Hsu DI, Nguyen M, Nguyen L et al. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010; 65: 1765-70.
12. Klevay MJ, Ernst EJ, Hollanbaugh JL et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-7.
13. Kludze-Forson M, Eschenauer GA, Kubin CJ et al. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 2010; 48: 436-9.
14. Parkins MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613-8.
15. Patel GP, Simon D, Scheetz M et al. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Amer J Ther 2009; 16: 508-11.
16. Taur Y, Cohen N, Dubnow S et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
17. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010; 10: 150.
18. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Pfizer, Inc. Diflucan Prescribing Information. New York: Pfizer, Inc., 2010.
21. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
22. Choi HK, Jeong SJ, Lee HS et al. Blood stream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med 2009; 24: 263-9.
23. Dimopoulos G, Ntziora F, Rachiotis G et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106: 523-9.
24. Kovacicova G, KrupovaY, LovaszovaMet al.Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother 2000; 6: 216-21.
25. Slavin MA, Sorrell TC, Marriott D et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-51.
26. Krcmery V Jr, Spanik S, Kunova A et al. Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review. J Chemother (Florence) 1999; 11: 131-6.